Re: A lesson on futility analyses from the CETP inhibitors
in response to
by
posted on
May 12, 2017 11:14AM
Just a clarification, there are 3 CETP programs still alive. Merck's anacetrapib/REVEAL study as presented earlier, dalcetrapib in a Phase 3 trial in a genetically defined population, and Amgen's AMG-899 (formerly Dezima's TA-8995) which passed Phase 2 and yet to start Phase 3.